Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,253 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.11, for a total value of $243,219.83. Following the sale, the chief accounting officer directly owned 10,352 shares in the company, valued at $2,009,426.72. The trade was a 10.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $190.91, for a total transaction of $213,246.47.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $186.67 on Wednesday. The business has a fifty day moving average of $170.40 and a 200 day moving average of $152.93. The stock has a market cap of $11.49 billion, a P/E ratio of -31.27, a PEG ratio of 0.38 and a beta of 0.22. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period last year, the company posted $6.51 earnings per share. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can raise visibility and institutional interest and is a modest positive for sentiment. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: Management presented at the TD Cowen Health Care Conference; the transcript provides updates on strategy and pipeline but did not announce major new approvals or guidance changes likely to move the stock immediately. Conference Transcript
• Neutral Sentiment: A Zacks note discusses Jazz’s reliance on international sales and how revenue mix could affect analyst forecasts — useful for modeling risk/benefit but not an immediate catalyst unless estimates are revised. Zacks International Sales Analysis
• Negative Sentiment: Large insider sale by EVP Neena M. Patil: 55,600 shares sold (~$10.65M at ~ $191.56/share), representing roughly a 49% reduction in her stake — a sizable single insider liquidation that can pressure sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); these are meaningful percentage reductions and add to downward pressure. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing
• Negative Sentiment: CAO Patricia Carr executed multiple sales (1,253 and 1,117 shares recently), a smaller but repeated reduction that contributes to the pattern of insider selling. Patricia Carr Insider Trades

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after acquiring an additional 298,815 shares during the period. Capital World Investors boosted its position in Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after purchasing an additional 111,735 shares in the last quarter. LSV Asset Management boosted its position in Jazz Pharmaceuticals by 3.6% in the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after purchasing an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after purchasing an additional 145,865 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on JAZZ shares. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Finally, Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $214.57.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.